Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study
- PMID: 28288972
- PMCID: PMC5524026
- DOI: 10.1161/JAHA.116.005038
Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study
Abstract
Background: Atherosclerosis is a chronic inflammatory disease, with interleukin 6 (IL-6) as a major player in inflammation cascade. IL-6 blockade may reduce cardiovascular risk, but current treatments to block IL-6 also induce dyslipidemia, a finding with an uncertain prognosis.
Methods and results: We aimed to determine the endothelial function responses to the IL-6-blocking agent tocilizumab, anti-tumor necrosis factor α, and synthetic disease-modifying antirheumatic drug therapies in patients with rheumatoid arthritis in a 16-week prospective study. Sixty consecutive patients with rheumatoid arthritis were enrolled. Tocilizumab and anti-tumor necrosis factor α therapy were started in 18 patients each while 24 patients were treated with synthetic disease-modifying antirheumatic drugs. Forty patients completed the 16-week follow-up period. The main outcome was flow-mediated dilation percentage variation before and after therapy. In the tocilizumab group, flow-mediated dilation percentage variation increased statistically significantly from a pre-treatment mean of (3.43% [95% CI, 1.28-5.58] to 5.96% [95% CI, 3.95-7.97]; P=0.03). Corresponding changes were 4.78% (95% CI, 2.13-7.42) to 6.75% (95% CI, 4.10-9.39) (P=0.09) and 2.87% (95% CI, -2.17 to 7.91) to 4.84% (95% CI, 2.61-7.07) (P=0.21) in the anti-tumor necrosis factor α and the synthetic disease-modifying antirheumatic drug groups, respectively (both not statistically significant). Total cholesterol increased significantly in the tocilizumab group from 197.5 (95% CI, 177.59-217.36) to 232.3 (201.62-263.09) (P=0.003) and in the synthetic disease-modifying antirheumatic drug group from 185.8 (95% CI, 169.76-201.81) to 202.8 (95% CI, 176.81-228.76) (P=0.04), but not in the anti-tumor necrosis factor α group. High-density lipoprotein did not change significantly in any group.
Conclusions: Endothelial function is improved by tocilizumab in a high-risk population, even as it increases total cholesterol and low-density lipoprotein levels.
Keywords: dyslipidemia; endothelial function; inflammation; tocilizumab.
© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Figures



Similar articles
-
[The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].Zhonghua Nei Ke Za Zhi. 2013 Apr;52(4):323-9. Zhonghua Nei Ke Za Zhi. 2013. PMID: 23925361 Clinical Trial. Chinese.
-
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7. Lancet. 2016. PMID: 27287832 Clinical Trial.
-
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940. Arthritis Rheum. 2008. PMID: 18821691 Clinical Trial.
-
Interleukin-6 in rheumatoid arthritis.Curr Opin Rheumatol. 2006 May;18(3):277-81. doi: 10.1097/01.bor.0000218949.19860.d1. Curr Opin Rheumatol. 2006. PMID: 16582692 Review.
-
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.Arch Pharm Res. 2015;38(5):575-84. doi: 10.1007/s12272-015-0569-8. Epub 2015 Feb 4. Arch Pharm Res. 2015. PMID: 25648633 Review.
Cited by
-
Immuno-cardio-oncology: Killing two birds with one stone?Front Immunol. 2022 Nov 17;13:1018772. doi: 10.3389/fimmu.2022.1018772. eCollection 2022. Front Immunol. 2022. PMID: 36466820 Free PMC article. Review.
-
A History of Preterm Delivery Is Associated with Aberrant Postpartal MicroRNA Expression Profiles in Mothers with an Absence of Other Pregnancy-Related Complications.Int J Mol Sci. 2021 Apr 14;22(8):4033. doi: 10.3390/ijms22084033. Int J Mol Sci. 2021. PMID: 33919834 Free PMC article.
-
Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis.Rheumatol Ther. 2020 Sep;7(3):473-516. doi: 10.1007/s40744-020-00219-2. Epub 2020 Jul 30. Rheumatol Ther. 2020. PMID: 32734482 Free PMC article. Review.
-
The Role of IL-6 and ET-1 in the Diagnosis of Coronary MicroVascular Disease in Women.J Pers Med. 2021 Sep 27;11(10):965. doi: 10.3390/jpm11100965. J Pers Med. 2021. PMID: 34683106 Free PMC article.
-
Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease.Front Cardiovasc Med. 2018 May 30;5:56. doi: 10.3389/fcvm.2018.00056. eCollection 2018. Front Cardiovasc Med. 2018. PMID: 29900175 Free PMC article.
References
-
- Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126. - PubMed
-
- Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high‐grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–2963. - PubMed
-
- McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N. Effect of interleukin‐6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo‐controlled study. Ann Rheum Dis. 2013;1–9. - PMC - PubMed
-
- Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. N Engl J Med. 2008;359:2195–2207. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical